U.S. health regulators' have approved the sale of Vivus Inc's diet pill, Qsymia, through retail pharmacies. This is a significant development for the company and is a shot in the arm for the direct-to-consumer campaign scheduled to be introduced later this year.
This announcement gave a good boost to Vivus shares, which rose as much as 6 percent to $12.35 on the Nasdaq.
The company is working towards increasing the commercialization support for the diet pill.
The company is also in talks with insurers and pharmacy benefit managers to improve Qsymia's reimbursement.